Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 6
1981 23
1982 35
1983 37
1984 69
1985 148
1986 210
1987 155
1988 174
1989 250
1990 185
1991 239
1992 231
1993 223
1994 230
1995 286
1996 260
1997 270
1998 245
1999 287
2000 252
2001 229
2002 255
2003 288
2004 296
2005 343
2006 322
2007 342
2008 406
2009 385
2010 416
2011 428
2012 453
2013 486
2014 503
2015 548
2016 502
2017 514
2018 529
2019 570
2020 698
2021 748
2022 714
2023 643
2024 194

Text availability

Article attribute

Article type

Publication date

Search Results

13,646 results

Results by year

Filters applied: . Clear all
Page 1
Imipenem.
Hellinger WC, Brewer NS. Hellinger WC, et al. Mayo Clin Proc. 1991 Oct;66(10):1074-81. doi: 10.1016/s0025-6196(12)61732-7. Mayo Clin Proc. 1991. PMID: 1921491 Review.
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. ...Like the penicillins, imipenem has inhibitory activity against enterococci. Daily doses may range from 500 mg to 1 g, every 6 to 8 hours, in patient …
Imipenem is the first of a new class of beta-lactam antibiotics, the carbapenems, to be released for clinical use. ...Like the penici …
Imipenem-cilastatin.
Dinsmoor MJ. Dinsmoor MJ. Obstet Gynecol Clin North Am. 1992 Sep;19(3):475-82. Obstet Gynecol Clin North Am. 1992. PMID: 1436925 Review.
Imipenem-cilastatin, with its broad spectrum of activity and relative safety, offers an excellent alternative for the treatment of many obstetric and gynecologic infections. ...Misuse and overuse of imipenem-cilastatin will result in the further development of resis …
Imipenem-cilastatin, with its broad spectrum of activity and relative safety, offers an excellent alternative for the treatment of ma …
Imipenem-Cilastatin-Relebactam: A Novel beta-Lactam-beta-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Smith JR, Rybak JM, Claeys KC. Smith JR, et al. Pharmacotherapy. 2020 Apr;40(4):343-356. doi: 10.1002/phar.2378. Epub 2020 Mar 9. Pharmacotherapy. 2020. PMID: 32060929 Review.
Relebactam is a beta-lactamase inhibitor with the ability to inhibit a broad spectrum of beta-lactamases such as class A and class C beta-lactamases, including carbapenemases. The addition of relebactam to imipenem restores imipenem activity against several imipe …
Relebactam is a beta-lactamase inhibitor with the ability to inhibit a broad spectrum of beta-lactamases such as class A and class C beta-la …
New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.
O'Donnell JN, Lodise TP. O'Donnell JN, et al. Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0025622. doi: 10.1128/aac.00256-22. Epub 2022 Jun 21. Antimicrob Agents Chemother. 2022. PMID: 35727059 Free PMC article. Review.
Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel beta-lactam/beta-lactamase inhibitor combination with expanded microbiologic activity against carbapenem-resistant non-Morganellaceae Enterobacterales (CR-NME) and difficult-to-treat (DTR) Pseudomonas aeruginosa. …
Imipenem (IMI)/cilastatin/relebactam (REL) (I/R) is a novel beta-lactam/beta-lactamase inhibitor combination with expanded microbiolo …
Imipenem.
Salaria M. Salaria M. Indian Pediatr. 2001 Dec;38(12):1370-3. Indian Pediatr. 2001. PMID: 11752734 Review. No abstract available.
Comparative review of the carbapenems.
Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. Zhanel GG, et al. Drugs. 2007;67(7):1027-52. doi: 10.2165/00003495-200767070-00006. Drugs. 2007. PMID: 17488146 Review.
Imipenem, meropenem and doripenem have in vivo half lives of approximately 1 hour, while ertapenem has a half-life of approximately 4 hours making it suitable for once-daily administration. ...The current role for imipenem/cilastatin and meropenem in therapy remains …
Imipenem, meropenem and doripenem have in vivo half lives of approximately 1 hour, while ertapenem has a half-life of approximately 4 …
Imipenem and aztreonam.
Sobel JD. Sobel JD. Infect Dis Clin North Am. 1989 Sep;3(3):613-24. Infect Dis Clin North Am. 1989. PMID: 2671142 Review.
Carbapenems: past, present, and future.
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Papp-Wallace KM, et al. Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Antimicrob Agents Chemother. 2011. PMID: 21859938 Free PMC article. Review.
We also highlight important features of the carbapenems that are presently in clinical use: imipenem-cilastatin, meropenem, ertapenem, doripenem, panipenem-betamipron, and biapenem. ...
We also highlight important features of the carbapenems that are presently in clinical use: imipenem-cilastatin, meropenem, ertapenem …
Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.
Benfield P, Chrisp P. Benfield P, et al. Pharmacoeconomics. 1992 Jun;1(6):443-59. doi: 10.2165/00019053-199201060-00005. Pharmacoeconomics. 1992. PMID: 10147024 Review.
Imipenem/cilastatin possesses a very broad spectrum of antibacterial activity that encompasses the range of Gram-negative and Gram-positive aerobes and anaerobes usually associated with intra-abdominal and other polymicrobial infections. ...The available pharmacoeconomic s …
Imipenem/cilastatin possesses a very broad spectrum of antibacterial activity that encompasses the range of Gram-negative and Gram-po …
Imipenem/cilastatin-associated hiccups.
Lucena M, Andrade R, Cabello M, Clavijo E, Queipo de Llano E. Lucena M, et al. Ann Pharmacother. 1992 Nov;26(11):1459. doi: 10.1177/106002809202601125. Ann Pharmacother. 1992. PMID: 1477457 No abstract available.
13,646 results
You have reached the last available page of results. Please see the User Guide for more information.